RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Grande, E.
Espinosa-Olarte, P.
Serrano, R.
Jimenez, P.
Alonso, T.
Benavent, M.
Capdevila Castillon, J.
Lacasta, A.
Yaya Tur, R.
Carmona, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
